XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update [Yahoo! Finance]
XORTX Therapeutics Inc. (XRTX)
Company Research
Source: Yahoo! Finance
CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, highlights recent peer-reviewed, independent, published research reports that expand current knowledge that genetic factors are linked to the over-expression of xanthine oxidase (“XO”), high chronic uric acid concentrations in the blood and gout. These ground breaking findings further support the Company's approach to treating gout, kidney and other diseases by inhibiting XO. Historically, high uric acid concentration in the blood has been associated with increased incidence of gout, inflammation and health consequences, attributed to diet and lifestyle choices. Xanthine oxidase is an essential enzyme within the uric acid metabolic pathway and is required for the breakdown of purine nucleotides. The
Show less
Read more
Impact Snapshot
Event Time:
XRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XRTX alerts
High impacting XORTX Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
XRTX
News
- XORTX Therapeutics Says Published Research Supports Company Approach to Gout Treatment [Yahoo! Finance]Yahoo! Finance
- XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update [Canadian Business Journal (Canada)]Canadian Business Journal
- XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate UpdateGlobeNewswire
- XORTX Announces Closing of US$1.1 Million Registered Direct Offering [Canadian Business Journal (Canada)]Canadian Business Journal
- XORTX Announces Closing of US$1.1 Million Registered Direct OfferingGlobeNewswire
XRTX
Sec Filings
- 1/2/26 - Form 6-K
- 11/17/25 - Form 6-K
- 10/31/25 - Form 6-K
- XRTX's page on the SEC website